Q2FY22 Result Preview - Healthcare - ICICI Direct

Continuity of domestic formulations growth with increasing share of non-Covid portfolio is likely to drive Q2FY22 sales even as expected weakness in the US generics space could act as a spoiler for overall momentum. The I-direct healthcare universe (12 coverage companies) is expected to post YoY growth of ~5.5% to ~Rs. 46123 crore. Domestic formulations (select pack) are expected to grow ~14% to Rs. 11219 crore due to continuous traction from acute segment (momentum began from Q1) besides normalised trend in the chronic segment. We expect a significant shift in growth momentum from Covid to non-Covid portfolio on the back of receding active cases and growing vaccination drive across the country.

For details, click on the link below: Link to the report

Source : Equity Bulls

Keywords

Healthcare Q2FY22 ResultPreview ICICIDirect